[go: up one dir, main page]

CL2018003377A1 - Compuestos novedosos para tratar enfermedades parasitarias. (divisional solicitud 201803187) - Google Patents

Compuestos novedosos para tratar enfermedades parasitarias. (divisional solicitud 201803187)

Info

Publication number
CL2018003377A1
CL2018003377A1 CL2018003377A CL2018003377A CL2018003377A1 CL 2018003377 A1 CL2018003377 A1 CL 2018003377A1 CL 2018003377 A CL2018003377 A CL 2018003377A CL 2018003377 A CL2018003377 A CL 2018003377A CL 2018003377 A1 CL2018003377 A1 CL 2018003377A1
Authority
CL
Chile
Prior art keywords
novel compounds
divisional application
parasitic diseases
treat parasitic
treat
Prior art date
Application number
CL2018003377A
Other languages
English (en)
Inventor
Tsutomu Akama
David Scott Carter
Jason S Halladay
Robert T Jacobs
Yang Liu
Jacob J Plattner
Yong-Kang Zhang
Michael John Witty
Original Assignee
Anacor Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anacor Pharmaceuticals Inc filed Critical Anacor Pharmaceuticals Inc
Publication of CL2018003377A1 publication Critical patent/CL2018003377A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/14Ectoparasiticides, e.g. scabicides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/027Organoboranes and organoborohydrides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

LA PRESENTE INVENCIÓN PROPORCIONA CIERTOS COMPUESTOS DE ÉSTER DE OXABOROL Y COMPOSICIONES DE LOS MISMOS QUE SON ÚTILES PARA TRATAR ENFERMEDADES ASOCIADAS CON PARÁSITOS, TALES COMO LA TRIPANOSOMIASIS ANIMAL AFRICANA.
CL2018003377A 2016-05-12 2018-11-27 Compuestos novedosos para tratar enfermedades parasitarias. (divisional solicitud 201803187) CL2018003377A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662335565P 2016-05-12 2016-05-12

Publications (1)

Publication Number Publication Date
CL2018003377A1 true CL2018003377A1 (es) 2019-01-11

Family

ID=58699201

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2018003187A CL2018003187A1 (es) 2016-05-12 2018-11-09 Ésteres de oxaborol y sus usos.
CL2018003377A CL2018003377A1 (es) 2016-05-12 2018-11-27 Compuestos novedosos para tratar enfermedades parasitarias. (divisional solicitud 201803187)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2018003187A CL2018003187A1 (es) 2016-05-12 2018-11-09 Ésteres de oxaborol y sus usos.

Country Status (32)

Country Link
US (5) US10562921B2 (es)
EP (2) EP3578562B1 (es)
JP (2) JP6715957B2 (es)
KR (2) KR102243775B1 (es)
CN (2) CN109503637B (es)
AR (2) AR108450A1 (es)
AU (2) AU2017263785B2 (es)
BR (2) BR122023022427A2 (es)
CA (1) CA3023490C (es)
CL (2) CL2018003187A1 (es)
CO (1) CO2018012077A2 (es)
CR (2) CR20180560A (es)
DK (1) DK3578562T3 (es)
EA (2) EA036661B1 (es)
EC (2) ECSP18091065A (es)
ES (1) ES2882782T3 (es)
HK (1) HK1258717A1 (es)
HU (1) HUE056320T2 (es)
IL (2) IL262453A (es)
MA (1) MA44968A (es)
MX (2) MX384421B (es)
NI (2) NI201801172A (es)
NZ (1) NZ746906A (es)
PE (2) PE20191077A1 (es)
PT (1) PT3578562T (es)
SG (1) SG11201809237RA (es)
TN (2) TN2018000351A1 (es)
TW (1) TWI629279B (es)
UA (2) UA121354C2 (es)
UY (2) UY37236A (es)
WO (1) WO2017195069A1 (es)
ZA (1) ZA201901168B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10070649B2 (en) 2013-01-30 2018-09-11 Agrofresh Inc. Volatile applications against pathogens
US11039617B2 (en) 2013-01-30 2021-06-22 Agrofresh Inc. Large scale methods of uniformly coating packaging surfaces with a volatile antimicrobial to preserve food freshness
WO2017155879A1 (en) 2016-03-07 2017-09-14 Agrofresh Inc. Synergistic methods of using benzoxaborole compounds and preservative gases as an antimicrobial for crops
CN109503637B (zh) * 2016-05-12 2021-03-16 安纳考尔医药公司 用于治疗寄生虫疾病的化合物
MA71363A (fr) * 2017-11-09 2025-04-30 Novo Nordisk A/S L'acide 1-hydroxy-4-(trifluorométhyl)-1,3-dihydrobenzo[c] [1,2]oxaborole-6-carboxylique et son utilisation dans la synthèse de dérivés de liaison à l'albumine sensibles au glucose
US11834466B2 (en) 2017-11-30 2023-12-05 5Metis, Inc. Benzoxaborole compounds and formulations thereof
JP2020180170A (ja) * 2019-04-23 2020-11-05 東ソー株式会社 ハロゲン含有ポリエーテルポリオール組成物
US12271171B2 (en) 2022-01-10 2025-04-08 Ge Infrastructure Technology Llc Systems and methods for integrated condition monitoring for power system asset health scoring

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
GB9411587D0 (en) 1994-06-09 1994-08-03 Zeneca Ltd Compound, composition and use
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
JO3396B1 (ar) 2007-06-20 2019-10-20 Anacor Pharmaceuticals Inc جزيئات صغيرة تحتوي على البورون
WO2010045503A1 (en) * 2008-10-15 2010-04-22 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-protozoal agents
WO2010045505A1 (en) * 2008-10-15 2010-04-22 Anacor Pharmaceuticals, Inc Boron-containing small molecules as anti-protozoal agents
AP4039A (en) 2009-08-14 2017-02-28 Daitao Chen Boron-containing small molecules as antiprotozoal agents
PL2673281T3 (pl) 2011-02-07 2016-10-31 Zawierające bor wielozasadowe inhibitory pomp usuwających substancje z komórek bakteryjnych oraz ich zastosowania terapeutyczne
US10130096B2 (en) 2011-10-07 2018-11-20 Syngenta Participations Ag Method for protecting useful plants or plant propagation material
AR088669A1 (es) 2011-11-21 2014-06-25 Lilly Co Eli Derivados de dihidrodibenzo[c][1,2]oxaborol y dihidroisoxazol utiles para el control de ectoparasitos
US8669207B1 (en) 2013-01-30 2014-03-11 Dow Agrosciences, Llc. Compounds and compositions
WO2015013318A1 (en) 2013-07-22 2015-01-29 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
SI3030519T1 (sl) 2013-08-09 2022-04-29 Glaxosmithkline Intellectual Property (No.2) Limited Triciklične benzoksaborolne spojine in njihove uporabe
WO2015097276A1 (en) * 2013-12-23 2015-07-02 Syngenta Participations Ag Benzoxaborole fungicides
EP3337809A1 (en) * 2015-08-17 2018-06-27 Syngenta Participations Ag 1-hydroxy-3h-2,1-benzoxaborole derivatives and their use as microbiocides
CN109503637B (zh) * 2016-05-12 2021-03-16 安纳考尔医药公司 用于治疗寄生虫疾病的化合物

Also Published As

Publication number Publication date
JP2019520326A (ja) 2019-07-18
BR112018071931A2 (pt) 2019-02-05
US20210101916A1 (en) 2021-04-08
EP3578562B1 (en) 2021-06-23
CN109503637A (zh) 2019-03-22
EA036661B1 (ru) 2020-12-04
IL263161A (en) 2018-12-31
PE20190119A1 (es) 2019-01-17
EA201892203A1 (ru) 2019-04-30
MX2018015410A (es) 2019-05-27
US20170327519A1 (en) 2017-11-16
KR20190005982A (ko) 2019-01-16
US20250304603A1 (en) 2025-10-02
ZA201901168B (en) 2024-08-28
ECSP18091065A (es) 2019-07-31
AU2017263785B2 (en) 2019-10-03
BR122018076188A2 (pt) 2019-09-10
CA3023490A1 (en) 2017-11-16
UY37980A (es) 2020-06-30
AU2018264116A1 (en) 2018-12-06
CA3023490C (en) 2021-06-08
EP3455227A1 (en) 2019-03-20
SG11201809237RA (en) 2018-11-29
MX384421B (es) 2025-03-14
EA201892475A1 (ru) 2019-04-30
UY37236A (es) 2018-01-02
MX386294B (es) 2025-03-11
JP2019081770A (ja) 2019-05-30
UA121354C2 (uk) 2020-05-12
IL263161B (en) 2022-05-01
CL2018003187A1 (es) 2019-01-11
AR108450A1 (es) 2018-08-22
EP3578562A1 (en) 2019-12-11
US11578087B2 (en) 2023-02-14
WO2017195069A1 (en) 2017-11-16
NI201801172A (es) 2019-04-10
HK1258717A1 (zh) 2019-11-15
US10562921B2 (en) 2020-02-18
AU2017263785A1 (en) 2018-10-25
HUE056320T2 (hu) 2022-02-28
UA120999C2 (uk) 2020-03-10
NZ746906A (en) 2020-06-26
TN2019000106A1 (en) 2020-10-05
PT3578562T (pt) 2021-08-05
NI201801171A (es) 2019-04-10
DK3578562T3 (da) 2021-07-12
TWI629279B (zh) 2018-07-11
US20200017531A1 (en) 2020-01-16
KR20190002695A (ko) 2019-01-08
EA034415B1 (ru) 2020-02-05
IL262453A (en) 2018-12-31
BR122023022427A2 (pt) 2023-12-26
JP6715957B2 (ja) 2020-07-01
MX2018013743A (es) 2019-05-02
ECSP19026702A (es) 2019-06-30
ES2882782T3 (es) 2021-12-02
US10882872B2 (en) 2021-01-05
CR20180560A (es) 2019-01-25
AU2018264116B2 (en) 2020-03-12
MA44968A (fr) 2019-03-20
TW201808968A (zh) 2018-03-16
CN109503637B (zh) 2021-03-16
TN2018000351A1 (en) 2020-06-15
KR102243775B1 (ko) 2021-04-22
CR20180502A (es) 2018-12-21
CO2018012077A2 (es) 2018-11-22
AR113543A2 (es) 2020-05-13
JP6715966B2 (ja) 2020-07-01
KR102231489B1 (ko) 2021-03-23
CN109153688A (zh) 2019-01-04
US20230132298A1 (en) 2023-04-27
PE20191077A1 (es) 2019-08-20

Similar Documents

Publication Publication Date Title
CL2018003377A1 (es) Compuestos novedosos para tratar enfermedades parasitarias. (divisional solicitud 201803187)
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
CL2019001744A1 (es) Derivados de benzoxazol como inmunomoduladores.
CO2017011484A2 (es) Inhibidores de bromodominio
UY37134A (es) Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4
MX2017012699A (es) Compuestos heterociclicos como inhibidores de demetilasa 1 especifica de lisina (lsd1).
CL2017001459A1 (es) Biarilo compuestos útiles para el tratamiento de enfermedades humanas en oncología, neurología e inmunología
EA201890052A1 (ru) Регуляторы nrf2
CR20160229A (es) Inhibidires de bromodominio
CO2018007221A2 (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj)
GT201800020A (es) Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r)
UY37169A (es) Análogos de 1,4-dihidropirimidin-5-carboxamidas como agonistas de apj y composiciones que los contienen
UY36949A (es) 2,4-dihidroxi-nicotinamidas como agonistas de apj
CL2020000085A1 (es) Moduladores de nlrp3.
CR20200464A (es) Compuestos diólicos de aminopirazina como inhibidores de pi3k-y
CL2018000611A1 (es) Sales de un inhibidor de pim quinasa
ECSP19066721A (es) Inhibidores duales de magl y faah
MX2019000982A (es) Compuestos y composiciones y usos de los mismos.